Merger Momentum: Tracking the Margin Expansion in a Consolidated Aster DM

Aster DM Quality Care enters Q2 as a fully consolidated entity, five months post-merger with Quality Care India (effective Jul 1, 2026). The combined proforma delivered ₹2,597 Cr revenue (+20% YoY) and ₹576 Cr EBITDA (+30%) in Q1, with margins expanding to 22.2%. Q2 will test whether the management can sustain revenue momentum while driving EBITDA margins toward the 24-25% long-term guidance. The test: integration execution, pricing power post-consolidation, and cost synergy realization.

A strong Q2 would show revenue growing ₹2,750 Cr+ (maintaining the 20%+ YoY proforma trajectory), EBITDA margin approaching or hitting 23-24%, and management confidently guiding toward the 24-25% target by FY28-29. Profit growth would accelerate as one-time merger charges moderate. The bed expansion at Trivandrum would be on track, and the newly acquired STS Holdings stake (Bangladesh, 14.21%, announced Aug 28) would begin contributing operationally. A weak print would show revenue decelerating below 18% YoY, EBITDA margin stalling below 22%, or management deferring margin guidance due to integration costs. PAT growth would lag EBITDA growth, signaling stranded costs post-merger. Delayed capex rollout or underperformance of the consolidated Quality Care network would raise questions about execution.

Yes, so far. Aster DM has executed the merger cleanly, consolidated financials are strong, and Q1 proforma results exceeded Street expectations on EBITDA. Revenue growth of 20%+ is in line with management's stated ambition to grow organically post-merger. The EBITDA margin trajectory (22.2% → 24-25% in 2-3 years) is credible given the low operating gearing of consolidated Quality Care and the revenue scale now achieved (combined entity is third-largest hospital network in India by revenue and beds). Headwinds are execution risk (integration, cost synergy capture) and industry-wide tariff pressures, but no material off-track signals yet.